Immune response in diabetics discussed at AGU

Manama, A scientific study conducted at the Arabian Gulf University (AGU) examined the immune response of type 2 diabetes who have high and low levels of C-peptide related to peripheral neuropathy.

The study which was done by researcher Noora Ali Al Hamar as part of the requirements to earn a PhD in Molecular Medicine and Genetic Science, recommended carrying out further studies that contain a huge number of samples, especially that this disease is wide-spreading across Bahrain and GCC States.

The importance of this research stems from the fact that it’s linked to the complications that strain the patients. We need to expand with regards to the conduction of more comprehensive studies that include studying all the factors and complications that diabetics suffer from, said the researcher.

The study covered type 2 diabetes patients who have peripheral neuropathy and it used C-peptide as a tool for examination as it plays a key role in pathological mechanisms of peripheral neuropathy in diabetics. The researcher noticed that the C-peptide material played a key role in reducing some of the effects of inflammatory resulted from peripheral neuropathy.

Al Hamar pointed out that the material could be used for the treatment of type 2 diabetes patients to prevent the expansion of neurological problems and complications associated with type 2 diabetes. The study included 131 diabetics and 81 nondiabetics from Bahrain. Furthermore, the response of cytokines was estimated at the LRNA DNA level, and the Enzyme-Linked Immunosorbent Assay (ELISA) scale was used to measure cytokine levels in the supernatant of cultured cells from the studied groups.

She added that the study didn’t find statistically significant differences when comparing the effects of C-peptide in the production of cytokines with positive control in all the studied groups.

In the future, this substance (C-peptide) will undoubtedly reduce the problems or causes of the nerve limbs and the consequent suffering of patients with type 2 diabetes, Al Hamar said.

Source: Bahrain News Agency